Nobuo Nagano
Laboratory of Pharmaceutical Development
Kirin Brewery Co.
Ltd., Gunma
Japan
Name/email consistency: high
- Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Nagano, N. Pharmacol. Ther. (2006)
- Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nagano, N., Miyata, S., Abe, M., Wakita, S., Kobayashi, N., Wada, M. Nephrol. Dial. Transplant. (2006)
- Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. Nagano, N., Nemeth, E.F. J. Pharmacol. Sci. (2005)
- Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats. Nagano, N., Miyata, S., Obana, S., Kobayashi, N., Abe, M., Fukushima, N., Wada, M. Nephrol. Dial. Transplant. (2003)
- Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nagano, N., Miyata, S., Obana, S., Kobayashi, N., Fukushima, N., Burke, S.K., Wada, M. Nephrol. Dial. Transplant. (2003)
- Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nagano, N., Miyata, S., Obana, S., Eto, N., Fukushima, N., Burke, S.K., Wada, M. Nephron (2001)